Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Proposed merger-of-equals with Indivior remains pending, with investor presentation scheduled for August 3, 2026.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Proposed merger-of-equals with Indivior remains pending, with investor presentation scheduled for August 3, 2026
- Indivior plans Form S-4 filing containing the joint proxy statement/prospectus required for shareholder voting
- Completion depends on shareholder and regulatory approvals, closing conditions, and absence of competing proposals
- Fixed exchange ratio exposes Supernus and Indivior shareholders to market-price changes before closing
- Additional indebtedness to fund a Special Dividend could increase leverage at the combined company
Item EX-99.1 · Exhibit EX-99.1
- Proposed stock-for-stock merger of equals with Indivior, targeted to close in Q4 2026 pending shareholder and regulatory approvals
- Supernus shareholders receive 1.5401 Indivior shares per share, owning 43.5% of the combined company
- Combined CNS portfolio targets $2.162B LTM revenue, 11 medicines, and four therapeutic areas
- At least $125M anticipated annual cost synergies, lifting pro forma Adjusted EBITDA to $888M and margin to 41%
- Indivior plans a $1B pre-closing dividend funded partly by $650M debt, resulting in pro forma net leverage below 1x
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.